A M Gonzalez-Angulo
Overview
Explore the profile of A M Gonzalez-Angulo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1092
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harano K, Lei X, Gonzalez-Angulo A, Murthy R, Valero V, Mittendorf E, et al.
Breast Cancer Res Treat
. 2016 Aug;
159(2):367-74.
PMID: 27522517
Trastuzumab-based treatment has dramatically improved the outcomes of HER2-positive (HER2+) metastatic breast cancer (MBC) patients, with some patients achieving prolonged survival times. In this study, we aim to identify factors...
2.
Bastos E, Brentani H, Pereira C, Polpo A, Lima L, Puga R, et al.
PLoS One
. 2016 May;
11(5):e0154325.
PMID: 27152840
Unlabelled: Breast cancer (BC) in young adult patients (YA) has a more aggressive biological behavior and is associated with a worse prognosis than BC arising in middle aged patients (MA)....
3.
Boutros C, Mazouni C, Lerebours F, Stevens D, Lei X, Gonzalez-Angulo A, et al.
Br J Cancer
. 2015 Feb;
112(6):992-7.
PMID: 25668007
Background: The detection of synchronous metastases at primary diagnosis of breast cancer (BC) affects its initial management. A risk calculator that incorporates many factors to evaluate an individual's risk of...
4.
Gonzalez-Angulo A, Parinyanitikul N, Lei X, Mittendorf E, Zhang H, Valero V, et al.
Br J Cancer
. 2015 Jan;
112(4):630-5.
PMID: 25584488
Purpose: To study the impact of adjuvant trastuzumab among patients achieving a pathologic complete response (pCR) after trastuzumab-based neoadjuvant systemic therapy (NST). Patients And Methods: Patients with primary HER2-positive breast...
5.
Dillon L, Bean J, Yang W, Shee K, Symonds L, Balko J, et al.
Oncogene
. 2014 Oct;
34(30):3968-76.
PMID: 25284585
Phosphatidylinositol 3-kinase (PI3K) promotes cancer cell survival, migration, growth and proliferation by generating phosphatidylinositol 3,4,5-trisphosphate (PIP3) in the inner leaflet of the plasma membrane. PIP3 recruits pleckstrin homology domain-containing proteins...
6.
Gonzalez-Angulo A, Akcakanat A, Liu S, Green M, Murray J, Chen H, et al.
Ann Oncol
. 2014 Mar;
25(6):1122-7.
PMID: 24669015
Background: Everolimus synergistically enhances taxane-induced cytotoxicity in breast cancer cells in vitro and in vivo in addition to demonstrating a direct antiproliferative activity. We aim to determine pharmacodynamics changes and...
7.
Dawood S, Lei X, Dent R, Gupta S, Sirohi B, Cortes J, et al.
Ann Oncol
. 2014 Mar;
25(6):1143-51.
PMID: 24669011
Background: Our group has previously reported that women with inflammatory breast cancer (IBC) continue to have worse outcome compared with those with non-IBC. We undertook this population-based study to see...
8.
Masuda H, Brewer T, Liu D, Iwamoto T, Shen Y, Hsu L, et al.
Ann Oncol
. 2013 Dec;
25(2):384-91.
PMID: 24351399
Background: Subtypes defined by hormonal receptor (HR) and HER2 status have not been well studied in inflammatory breast cancer (IBC). We characterized clinical parameters and long-term outcomes, and compared pathological...
9.
Sohn J, Do K, Liu S, Chen H, Mills G, Hortobagyi G, et al.
Ann Oncol
. 2013 Aug;
24(10):2522-2526.
PMID: 23925999
Background: In this study, we used functional proteomics to determine the molecular characteristics of residual triple receptor-negative breast cancer (TNBC) patients after neoadjuvant systemic chemotherapy (NCT) and their relationship with...
10.
Kim M, Allen P, Gonzalez-Angulo A, Woodward W, Meric-Bernstam F, Buzdar A, et al.
Ann Oncol
. 2013 Apr;
24(8):1999-2004.
PMID: 23562929
Background: We sought to determine the prognostic value of pathologic response to neoadjuvant chemotherapy with concurrent trastuzumab. Patients And Methods: Two hundred and twenty-nine women with HER2/neu (HER2)-overexpressing breast cancer...